Drug intelligence / Profile preview

paracetamol + phenylephrine + guaifenesin

Development stage
Phase 3
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

This is an oral combination drug containing three active ingredients: - Paracetamol (also known as acetaminophen): a non-opioid analgesic and antipyretic that reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system. - Phenylephrine: a sympathomimetic decongestant that acts as an alpha-1 adrenergic receptor agonist to constrict blood vessels in the nasal mucosa, reducing swelling and congestion. - Guaifenesin: an expectorant that increases the volume and reduces the viscosity of respiratory tract secretions, making coughs more productive. The combination is used for temporary relief of symptoms associated with colds or flu such as headache, fever, minor aches and pains, nasal congestion due to allergies or upper respiratory infections (including sinusitis), chest congestion from mucus buildup, and dry cough. It does not treat underlying infections[1][2][4].

Brand names
Tylenol Sinus SevereMucinex Sinus-MaxDayQuil SinexSudafed PE Pressure+Pain+Cough
Other names
acetaminophen + phenylephrine + guaifenesinacetaminophen; guaifenesin; phenylephrine
02

Targets

ADRA1A (α1A)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on paracetamol + phenylephrine + guaifenesin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + phenylephrine + guaifenesin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call